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Abstract Hospital acquired venous thromboembolism
(VTE) is a major source of morbidity and mortality, yet
proven prevention measures are often underutilized. The
lack of a validated VTE risk assessment model, difﬁculty
integrating VTE risk assessment and prevention protocols
into the routine process of care, and the lack of standard-
ized metrics for VTE prophylaxis have all been barriers.
Recently, a VTE risk assessment/prevention protocol has
been validated, leading to portable strategies achieving
breakthrough levels of adequate prophylaxis in a variety of
inpatient settings. VTE prevention protocol design and
implementation strategies have been collected in imple-
mentation guides available from the Society of Hospital
Medicine and the Agency for Healthcare Research and
Quality. These guides were the centerpieces of national
collaborative efforts to improve VTE involving over 150
medical centers, honing the approach to accelerate
improvement described in this article. Embedding a VTE
prevention protocol into admission, transfer, and periop-
erative order sets is a key strategy. A VTE prevention
protocol is deﬁned as a VTE risk assessment with no more
than three levels of risk, tightly linked to recommended
prophylaxis for each level. A balance between the need to
provide protocol guidance and the need for efﬁciency and
ease-of-use by the clinician must be maintained. The power
of this protocol driven approach is bolstered by a quality
improvement framework, multidisciplinary teams, ongoing
monitoring of the process, and real time identiﬁcation and
mitigation of non-adherents via a technique that measures
progress and prompts concurrent intervention, an approach
we call ‘‘measure-vention.’’
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Introduction
Pulmonary embolism (PE) and deep vein thrombosis
(DVT), collectively referred to as venous thromboembo-
lism (VTE), represent a major public health problem,
affecting hundreds of thousands of Americans each year
[1]. At least 100,000 deaths, and perhaps over 200,000
deaths, are attributable to VTE each year in the United
States alone [1]. VTE is primarily a problem of hospital-
ized and recently hospitalized patients [2, 3], and PE is
frequently estimated to be the most common preventable
cause of hospital death [4–6].
Pharmacologic methods to prevent VTE are safe,
effective, cost-effective, and advocated by authoritative
guidelines [7]. Even though the majority of medical and
surgical inpatients have multiple risk factors for VTE, large
prospective studies continue to demonstrate that these
preventive methods are signiﬁcantly underutilized, often
with only 30–50% eligible patients receiving prophylaxis
[8–12].
Recent investigations like (ENDORSE) [12] offer a
perspective of VTE prevention performance from around
the world. This cross sectional survey encompassed 358
medical centers from 32 countries. Only 58.5% of surgical
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DOI 10.1007/s11239-009-0405-4patients and 39.5% of medical patients were on prophylaxis
consistent with ACCP [7] guidelines, and the United States
performance was only marginally better than the world
mean, with less than 50% of medical patients receiving
guideline recommended prophylaxis.
The toll in preventable mortality and morbidity has not
gone unnoticed by those in health advocacy groups, policy
makers, and payers. The National Quality Forum has
already endorsed that each patient be evaluated for their
risk of VTE on admission and regularly thereafter [13], and
The Joint Commission is moving towards standards that
will hold medical centers accountable for ensuring that
patients will have VTE prophylaxis in place within 24 h of
hospital admission, and within 24 h of transfer to critical
care settings, or demonstrate a risk assessment or contra-
indications to justify why it is not in place [14]. Further-
more, the Centers for Medicare and Medicaid Services
(CMS) recently ruled that if a patient develops VTE during
hospitalization for total knee or hip replacement, the hos-
pital will not be paid for the added expense of that com-
plication [15].
Multiple reasons have been invoked to explain this
persistent under-utilization, in spite of good faith efforts in
medical centers to improve performance, and ever
increasing external pressures. These include a lack of
physician familiarity or agreement with guidelines,
underestimation of VTE risk, concern over risk of bleed-
ing, and the perception that the guidelines are resource
intensive or difﬁcult to implement in a practical fashion
[16]. While many VTE risk assessment models are avail-
able in the literature [17–21], the absence until just recently
of prospectively validated models, and issues regarding
ease of use have hampered widespread integration of VTE
risk assessments into order sets and inpatient practice.
Successful local and national VTE prevention efforts
Recognizing the importance of improving VTE prophy-
laxis, we initiated an Agency for Healthcare Research and
Quality (AHRQ) funded project in 2005 to optimize pre-
vention of hospital-acquired VTE in our 350 bed tertiary
care center, using techniques that could be replicated in a
variety of other institutions. A full description of tech-
niques used and the results obtained is in press [22] and
will be available elsewhere, but a few highlights are
instructive. We designed, piloted, and implemented a VTE
prevention protocol for all adult medical surgical patients,
via integration of a simple VTE risk assessment model into
admission and transfer order sets. Each level of VTE Risk
was ﬁrmly linked to a menu of acceptable prophylaxis
options, and we augmented the performance of the protocol
with methods such as audit and feedback, education, and
real-time identiﬁcation and mitigation of non-adherents to
the protocol.
For the ﬁrst time, a VTE risk assessment model/pre-
vention protocol was validated in a number of important
ways. Ease of use and inter-observer agreement for VTE
risk level and a judgment of ‘‘adequate’’ prophylaxis were
very high (kappa score 0.81 and 0.90, respectively), and the
VTE risk assessment model was predictive of VTE risk.
The percent of patients on adequate prophylaxis improved
each year, from 58% of sampled inpatients to over 98% of
inpatients sampled in the latter half of 2007 and all of 2008.
Signiﬁcant reductions for the risk of HA VTE [RR 0.69
(0.47–0.79)] and preventable HA VTE [RR 0.14 (0.06–
0.31)] occurred, and there was no detectable increase in
heparin induced thrombocytopenia or prophylaxis-related
bleeding as assessed by chart review of administrative data.
We have published implementation guides now avail-
able in both web and stand alone formats [23–25]. These
guides, drawing from our local experience as well as other
experts and improvement team leaders, take improvement
teams in a step-by-step fashion through the process of
effective VTE protocol design, implementation, and mon-
itoring. The principles outlined in our implementation
guides have served as a road map for a number of suc-
cessful mentored implementation collaborative efforts
administered via the Society of Hospital Medicine (SHM),
AHRQ, and more recently the Institute for Healthcare
Improvement (IHI). The advice and principles outlined
below have been tested and found to be effective and
practical in over 150 medical centers of all types (academic
and community, small and large, rural and urban, paper and
electronic order environments).
Overview of infrastructure: basic ingredients
for effective efforts
To implement effective protocols minimizing incidence of
hospital-acquired VTE, while at the same time minimizing
adverse outcomes, redesign is needed in both care delivery
and performance tracking. Essential elements to reach
breakthrough levels of improvement include:
• Institutional support and prioritization for the initiative,
expressed in terms of a commitment to standardize the
process of providing VTE prophylaxis, and reasonable
support to facilitate implementation and monitoring of
results.
• A multidisciplinary team or steering committee focused
on reaching VTE prophylaxis targets and reporting to
key medical staff committees. Physician leadership is a
necessary component of the team. High volume
providers such as hospitalists and critical care
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123physicians, or prominent surgery leaders, are desirable
to have as leaders for the improvement effort.
• Speciﬁc goals or aims which are ambitious, time-
deﬁned, and measurable.
• Protocols that standardize VTE risk assessment and
prophylaxis and embed this process in the ﬂow of
normal patient care.
• Reliable data collection and performance tracking
(suggested metrics described in more detail below),
with education and reﬁnement of the protocol driven by
the ongoing observation and measurement process.
As in all improvement efforts, we endorse piloting small
tests of change, and careful vetting of VTE prevention
order sets before attempting wide implementation.
The essential intervention: a VTE prevention protocol
We deﬁne a VTE prevention protocol to be a standardized
VTE risk assessment, linked to a menu of appropriate VTE
prophylaxis options for each level of risk [23–25]. Guid-
ance for management of patients with contraindications to
pharmacologic prophylaxis should also be included. The
best protocols provide decision support at the point of care,
and yet are user friendly and efﬁcient to use, and preserve
the ability to customize care for special patient situations or
circumstances [23–26].
Who administers the protocol?
Conceivably, anyone in the medical center (e.g. a nurse or
pharmacist) could administer the risk assessment model
and present the results to the physician for action. How-
ever, our collective experience suggests that the VTE
prevention protocol is most effective when embedded in
commonly used admission, transfer, and perioperative
order sets. Across VTE collaboratives, the physician con-
sistently appears to be in the best position to understand all
components of VTE risk, along with the possible contra-
indications to pharmacologic prophylaxis. Furthermore, an
immediate connection in time and space of the VTE risk
assessment to the ordering process makes for a more reli-
able and direct route for ordering adequate prophylaxis.
How should I design the risk assessment into the order
set?
We recommend integrating a simple text based model with
no more than three levels of VTE risk. An illustrative paper
order set is depicted in the Appendix. While this example
depicts enoxaparin as the low molecular weight heparin of
choice, local formulary issues and medical staff opinion
will dictate these choices, and with this illustration we are
not implying one is superior to the other.
At one extreme of VTE risk are patients that would
beneﬁt from both a low molecular weight heparin or
fondaparinux and mechanical prophylaxis (while not
depicted in this example, some institutions also offer
warfarin as an option for these high risk patients). Major
orthopedic surgery, multiple major trauma, spinal cord
injury with paresis, and abdominal/pelvic cancer patients
undergoing surgery are common choices for patients in this
very high risk category. Choices for renal insufﬁciency and
end stage renal disease are offered with simple caveats in
parentheses. In our medical center, 15–20% of our inpa-
tients fall into this highest risk category.
At the other extreme are patients at such low risk for
VTE they do not require any prophylaxis other than
education and ambulation. This model accepts a paradigm
in which almost all inpatients are at risk for VTE and
need pharmacologic prophylaxis, with the exception of
the few who are expected to be in the medical center for
less than 48 h, or who have a paucity of risk factors and
are fully and independently ambulating. This low risk
subset represents less than 5% of inpatients at our medical
center.
The majority of inpatients occupy the middle category
of VTE risk. While there is some evidence favoring low
molecular weight heparin (LMWH) versus unfractionated
heparin (UFH) in subsets of this population [27, 28], evi-
dence is fairly weak at this risk level, and either choice is
usually seen as acceptable. Note that UFH 5000 units dosed
every 12 h has been relegated a secondary role, suitable
only for underweight or geriatric patients. This choice is
admittedly somewhat arbitrary, but the trials comparing
LMWH to UFH regimens used 5000 units q 8 h dosing
schedules in the comparison arm [27–30]. On the whole,
there is more evidence for using UFH 5000 q 8 h schedules
compared to UFH 5000 q 12 h regimens. Attempts to tease
out populations in which UFH 5000 q 8 h is acceptable but
UFH 5000 q 12 h regimens are not are generally not worth
the effort, and lead to unnecessary clutter and complexity
to order sets.
Contraindications and a full listing of VTE risk factors
should not occupy precious ‘‘real estate’’ on the front page
of an order set, but should be readily accessible by
instructions embedded there. Sequential compression
devices are speciﬁcally listed as the default choice for
mechanical prophylaxis. Mechanical prophylaxis is rele-
gated to an adjunctive role, or as a ﬁrst line choice when
pharmacologic prophylaxis is not feasible. Aspirin is not
listed as an acceptable choice for DVT prophylaxis, which
is consistent with prominent guidelines [7]. Improvement
teams need not feel restricted in the design details of the
order set or the choices they offer for each level of risk,
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123providing they retain the most important design concepts
and avoid the most common errors outlined below.
Common errors in constructing/implementing a VTE
prevention order set
Not providing enough guidance: a prompt is not a protocol
Many centers have order sets that list options for VTE
prophylaxis without providing any guidance for which
choice is most appropriate or desirable. Mechanical pro-
phylaxis, varying pharmacologic agents with different
doses, and no prophylaxis are inappropriately offered as
equal options, even though most inpatients have signiﬁcant
VTE risk factors [7, 11], and in spite of strong evidence
based recommendations [7] relegating mechanical pro-
phylaxis to an adjunctive role for pharmacologic prophy-
laxis (unless there are contraindications to pharmacologic
prophylaxis).
Providing too much guidance: order sets can become too
complicated
It is tempting to create an order set that provides compre-
hensive guidance and outlines the best prophylaxis for the
entire spectrum of conditions. Improvement teams must
strike a ﬁne balance between providing a good risk
assessment for the great majority of the inpatient popula-
tion, yet keeping things simple and efﬁcient in everyday
use. We have encountered three page stand-alone order
VTE prophylaxis order sets that would provide excellent
guidance if used, but they simply collect dust and are
adapted by only a minority of providers. Some order sets
offer 4-6 levels of VTE risk, but the evidence to distinguish
the levels of risk, and the differences in attendant pro-
phylaxis choices, is often weak. We have found that 2–3
levels of VTE risk are enough.
Many centers have tried to adapt point based models
inspired by the pioneering work of Caprini and colleagues
[18, 21]. In theory, this model is attractive. Risk factors
depicting the clinical setting and the patient are assigned
points, and the cumulative point total is entered into the
order set, with guidance for prophylaxis hinging on this
cumulative point total. In practice, this risk assessment
method is often fraught with problems. Hurried clinicians
do not reliably add up the points for each risk, and inter-
observer agreement suffers as a result. The point scoring
system is somewhat arbitrary, and has not yet been vali-
dated in the literature. Most importantly, the point based
systems are too long and bulky to integrate into a variety of
existing order sets, and as a result, reliability of use and
wide adaption is problematic.
Offering non-pharmacologic prophylaxis as a ﬁrst line
option
Pharmacologic prophylaxis is recommended as the ﬁrst
line choice for inpatients at risk for VTE. Mechanical
prophylaxis can (and often should) be offered as an adjunct
to pharmacologic prophylaxis, but it should not be offered
as a ﬁrst line choice for prophylaxis in the absence of
contraindications to VTE prophylaxis.
Link between risk level and prophylaxis choices
are separated in time or space
Ideally, the VTE risk assessment is performed quickly, and
the choices for appropriate prophylaxis are directly and
inescapably linked to each level of risk. If the act of
ordering VTE prophylaxis is separated in any way from the
risk assessment, the reliability of ordering adequate pro-
phylaxis deteriorates.
Failure to revise pre-existing and conﬂicting order sets
Most institutions have a variety of admission, transfer, and
order sets in place. These order sets often already ‘‘touch’’
the majority of adult inpatients, and they often have a
highly variable approach to VTE prophylaxis embedded
within them. We strongly urge improvement teams to
examine all existing admission, transfer, and perioperative
order sets with reference to VTE prophylaxis. The
designers and users of these order sets should be approa-
ched to build consensus on using the redesigned, stan-
dardized, protocol-driven VTE prophylaxis orders, with the
intent to strip out all non-standardized VTE prevention
orders, and replace them with the new, standardized
version.
Modular versus stand alone orders
If the order set is constructed properly, it can often be
designed as a VTE prevention ‘‘module,’’ making it easier
to integrate into the pre-existing order sets referenced
above. This is preferable to order sets designed to stand
alone, but even stand alone orders can be integrated into
the ﬂow of admissions and transfers with a little ingenuity.
Clipping the VTE order set on to ‘‘History and Physical’’
forms or onto pre-existing order sets may increase adaption
to an acceptable level, though we prefer modular order set
design whenever possible.
Enhancing the power of the protocol
Skillful introduction of a good order set that reaches most
patients has often yielded observed VTE prophylaxis rates
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123of 70–85% (from baseline performance of 35–55%) in our
local experience and in collaborative VTE prevention
efforts. This performance boost is a great accomplishment,
but such an approach alone is not sufﬁcient. No matter how
clear and concise the order set is, it will not always be used
correctly. Moreover, acutely ill patients often have tran-
sient changes in the risk/beneﬁt ratio of using anticoagu-
lation, leading to lapses in VTE prophylaxis that persist
beyond transient bleeding risk. To reach higher levels of
performance under these constraints, a multifaceted
approach using a variety of techniques has been effective in
the literature [16, 22–25, 31–36] and in the collaborative.
Educational programs alone [32, 37, 38] are not generally
sufﬁcient to bring about reliable VTE prophylaxis, but are
needed to foster appropriate use of order sets and protocols.
Periodic audit and feedback and computerized decision
support can also be very effective [31, 39–43], particularly
when there is an institutional protocol to hold up as the
deﬁning standard for adequate prophylaxis, but some of the
more sophisticated tools are beyond the reach of many
improvement teams.
Situational awareness and measure-vention
One method to enhance the power of the VTE prevention
protocol has distinguished itself from all the others. This
method, which we call ‘‘measure-vention,’’ involves iden-
tifying and measuring patients on potentially inadequate
prophylaxis and intervening on them in real time. This
strategy has proven successful in a variety of environments
[22, 33]. The measure-vention technique for VTE pro-
phylaxis most commonly follows a series of steps as
described below.
The medication administration record (MAR) or an
automated report (often generated by pharmacy) is pre-
sented to front line staff, identifying the VTE prophylaxis
status of each patient on the ward. Advanced versions of
this approach have actually classiﬁed each patient on the
ward as being ‘‘green’’ (an order in place for therapeutic or
prophylactic anticoagulation), the ‘‘yellow’’ (mechanical
prophylaxis without pharmacologic prophylaxis), or ‘‘red’’
(no VTE prophylaxis orderd), see Fig. 1. Extracting this
information from the MAR into a report creates a situa-
tional awareness, calling for explicit action on the part of
the front line staff member.
The staff member (usually a staff nurse or charge nurse,
butsometimes apharmacist)isthen called uponto intervene
on patients that seem to be non-adherent to the protocol. For
example, if a patient is classiﬁed as red, nursing can be
authorized to place sequential compression devices on the
patient—and if there are no obvious bleeding problems and
anyVTEriskfactorispresent—canplaceasimpletemplated
note on the chart and text page the physician, asking them to
either place the patient on pharmacologic prophylaxis or
state the reason they choose not to do this. This method can
quickly bolster VTE prophylaxis rates to 95% [33], and
fatigue from alerts can be minimized if the intervention part
ofthestrategyisdeployedaftertheordersetislaunched.The
medical staff leadership and administration need to make
sure the front line staff are comfortable carrying out this
Fig. 1 The measure-vention
strategy depicted in this ﬁgure is
a real-time dashboard formatted
to classify patient’s VTE
prophylaxis status. In actual use
and as depicted in the online
version of this article, each
patient’s status is categorized as
red (no VTE prophylaxis
ordered), yellow (mechanical
prophylaxis only, with no
pharmacologic prophylaxis),
and green (pharmacologic or
therapeutic anticoagulation)
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unacceptable.
Measure-vention as described above provides the means
to establish reliable, easy to understand metrics for VTE
prophylaxis. The percent of patients on anticoagulation
based prophylaxis, and the percent of patients on any
prophylaxis, while not perfect metrics, are easy to assess
and relatively easy to automate. These measures are
actionable on the front line, yet are suitable for tracking,
trending, and creating roll-up reports that could be reported
to key medical staff committees and governing boards.
Dueling guidelines and other barriers
In many centers, implementing a standardized VTE pre-
vention protocol meets with resistance from one or more
groups of physicians, and more often than not, the
objecting physicians are orthopedists. While many ortho-
pedists are very comfortable with pharmacologic prophy-
laxis and will have no problem with this approach, we
estimate that about one third of centers run into stiff
resistance from their orthopedic physicians. This resistance
gained some momentum when the American Academy of
Orthopedic Surgeons (AAOS) disseminated a new guide-
line [44] that differs in many ways from the most promi-
nent guideline [7] from the American College of Chest
Physicians (ACCP). The AAOS guidelines, in a point of
distinction from the ACCP guidelines, allow the use of
aspirin as a prophylactic agent, in patients at high risk of
bleeding, and in patients at standard risk of bleed and
standard risk of PE with joint replacement. The differences
between the two guidelines are largely explained by the
viewpoint of the authors and the methods they used for
their supporting literature review. The AAOS guidelines
take the view that the literature underestimates the bleeding
risk of pharmacologic prophylaxis with joint replacement,
and that bleeding into the wound or joint can cause long
term joint problems. They also focused only on symp-
tomatic PE, discounting the morbidity caused by symp-
tomatic DVT, and discounting the relationship between
asymptomatic DVT found on routine screening and the
development of symptomatic problems.
Improvement teams faced with the resistant physician
group (be they orthopedic group or others) can not let this
resistance stop their efforts to improve VTE prophylaxis
for the larger population, but a pitched battle and man-
dating adherence to one standardized protocol is generally
counterproductive in this setting, especially in view of the
conﬂicting guidance from these two guidelines. Orthopedic
groups who feel strongly that they should follow AAOS
guidelines instead of ACCP guidelines should be ‘‘carved
out’’ of the standardization used for the rest of the adult
medical/surgical population, though they should be
expected to standardize their care within the conﬁnes of the
alternate guideline.
There are also guidelines from other sources concerning
VTE prevention [45, 46] covering special populations like
oncology patients and obstetrics/gynecology patients.
These guidelines are largely congruent with ACCP guide-
lines, but improvement teams should consider closely if
there are other services that should be allowed ‘‘carve out’’
status.
Summary
Hospital acquired VTE related morbidity and mortality are
hugepublichealthproblems,andimprovingperformanceon
VTE prevention is a moral and public health imperative.
Lessons gleaned from local success stories and national
collaborative efforts can accelerate improvement in this
vital area. Integrating a simple VTE risk assessment into
VTE prevention orders that are positioned to capture the
majority of admissions and transfers is an essential strategy.
The power of this protocol driven approach can be bolstered
by using a quality improvement framework, a multidisci-
plinary team approach, ongoing monitoring of the process,
and real time identiﬁcation and mitigation of non-adherents
via the measure-vention technique.
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